Pangalis G A, Roussou P A, Kittas C, Kokkinou S, Fessas P
Cancer. 1987 Feb 15;59(4):767-71. doi: 10.1002/1097-0142(19870215)59:4<767::aid-cncr2820590417>3.0.co;2-6.
The available staging systems for B-chronic lymphocytic leukemia (B-CLL) do not always predict the clinical course and the prognosis of the disease. In these systems, the pattern of bone marrow histology is not incorporated. In the current report we investigate the prognostic value of the diffuse or nondiffuse pattern of bone marrow involvement in 120 B-CLL patients in relation to their actuarial survival, and we compare these results with the actuarial survival based on the International Workshop system. In addition, we analyze the influence of the diffuse or nondiffuse pattern on the actuarial survival, in relation to the individual clinical stages (A, B, C). All patients were diagnosed and followed-up in the same Unit. Our patients were divided into Stage A (64), Stage B (22), and Stage C (34). They were also subdivided into those with a diffuse (46) and those with a nondiffuse (74) pattern of bone marrow histology. The difference in the actuarial survival in relation to their clinical stage (A, B, C) was statistically significant (P less than 0.025). A greater statistical difference (P less than 0.005) was found when the actuarial survival was analyzed in relation to the diffuse or nondiffuse pattern of bone marrow histology. No statistically significant differences could be found (P greater than 0.1), when the actuarial survival was calculated in every stage (A, B, C), on the basis of the diffuse or nondiffuse pattern of bone marrow histology. When our Stage A and B patients were analyzed for disease progression, in relation to the diffuse or nondiffuse bone marrow histology, it was found that 66.6% of the diffuse Stage A patients and 88% of the diffuse Stage B patients had disease progression as compared to only 8.6% for the nondiffuse Stage A patients and 33% for the nondiffuse Stage B patients. Our findings indicate that: the pattern of bone marrow histology in B-CLL patients is the single most important prognostic parameter in this disease; a clinicopathologic staging system for B-CLL may be justified; and the diffuse pattern of bone marrow histology could be considered as the best criterion for initiation of therapy in these patients.
用于B细胞慢性淋巴细胞白血病(B-CLL)的现有分期系统并不总能预测该疾病的临床病程和预后。在这些系统中,未纳入骨髓组织学模式。在本报告中,我们研究了120例B-CLL患者骨髓受累的弥漫性或非弥漫性模式对其精算生存率的预后价值,并将这些结果与基于国际研讨会系统的精算生存率进行比较。此外,我们分析了弥漫性或非弥漫性模式对精算生存率的影响,与个体临床分期(A、B、C)相关。所有患者均在同一科室进行诊断和随访。我们的患者分为A期(64例)、B期(22例)和C期(34例)。他们还被细分为骨髓组织学呈弥漫性(46例)和非弥漫性(74例)的患者。其精算生存率与临床分期(A、B、C)的差异具有统计学意义(P小于0.025)。当分析精算生存率与骨髓组织学的弥漫性或非弥漫性模式相关时,发现了更大的统计学差异(P小于0.005)。当根据骨髓组织学的弥漫性或非弥漫性模式在每个分期(A、B、C)计算精算生存率时,未发现统计学显著差异(P大于0.1)。当分析我们的A期和B期患者的疾病进展与弥漫性或非弥漫性骨髓组织学的关系时,发现弥漫性A期患者中有66.6%和弥漫性B期患者中有88%出现疾病进展,而非弥漫性A期患者中只有8.6%,非弥漫性B期患者中为33%。我们的研究结果表明:B-CLL患者的骨髓组织学模式是该疾病最重要的单一预后参数;B-CLL的临床病理分期系统可能是合理的;骨髓组织学的弥漫性模式可被视为这些患者开始治疗的最佳标准。